Emergent BioSolutions manufactures immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients exposed to anthrax and botulinum toxin. The company, which was founded in 1998, is based in Rockville, Maryland.